effector therapeutics stock symbol

Last Funding Type Post-IPO Equity. eFFECTOR Therapeutics: EFTR Stock Price Quote & News ... Complete eFFECTOR Therapeutics Inc. stock information by Barron's. View real-time EFTR stock price and news, along with industry-best analysis. eFFECTOR Therapeutics Inc., EFTR Quick Chart - (NAS) EFTR ... EFTR Stock Price and Chart — NASDAQ:EFTR — TradingView eFFECTOR Therapeutics News - EFTR | ADVFN Please note that any opinions, estimates or forecasts regarding eFFECTOR Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of eFFECTOR Therapeutics or its management. EFTR Stock Quote - eFFECTOR Therapeutics, Inc. Stock Price ... EFTR Interactive Stock Chart | eFFECTOR Therapeutics, Inc ... All News News Headlines . EFTR Stock Forecast, Price & News (eFFECTOR Therapeutics) Stock analysis for eFFECTOR Therapeutics Inc (LWAC) including stock price, stock chart, company news, key statistics, fundamentals and company profile. EFTR - Effector Therapeutics Stock Price History ... Their latest funding was raised on Aug 26, 2021 from a Post-IPO Equity round. The stock opened with a gain of 16.38% at $6.75 and touched an intraday high of $7.04, rising 21.38% against the last close of $5.80. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with . Phone Number 8589258215. eFFECTOR is a clinical stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to . EFTR eFFECTOR Therapeutics Inc — Stock Price and Discussion | Stocktwits. Description: eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).Its product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). Company Name: eFFECTOR Therapeutics Inc, Stock Symbol: EFTR, Industry: Biotechs, Total Posts: 14, Last Post: 10/8/2021 1:38:16 AM eFFECTOR Therapeutics (EFTR) stock price, charts, trades & the US's most popular discussion forums. Josh Enomoto on InvestorPlace | September 28, 2021. eFFECTOR Therapeutics Stock Might Be Worth the Risk in Small Quantities. Analyst Coverage. Company Type For Profit. eFFECTOR Therapeutics (NASDAQ: EFTR) stock price, news, charts, stock research, profile. Free forex prices, toplists, indices and lots more. Press down arrow for suggestions, or Escape to return to entry field. View the latest EFTR stock quote and chart on MSN Money. Complete eFFECTOR Therapeutics Inc. Wt stock information by Barron's. View real-time EFTRW stock price and news, along with industry-best analysis. SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference at 2:40 p.m. Effector Therapeutics is funded by 15 investors. Published: Jan 09, 2020 By Mark Terry. More. Georgian Ex-President Saakashvili Returns From Exile, Arrested On Eve Of Election. eFFECTOR Therapeutics (EFTR) Stock Price,News,Quote-Futubull. According to present data eFFECTOR Therapeutics's EFTR shares and potentially its market environment have been in bearish cycle last 12 months (if exists). Get the latest eFFECTOR Therapeutics Inc (EFTR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Effector Stock Statistic Functions Standard Deviation. Provide the latest EFFECTOR THERAPEUTICS(EFTR) market data, including prices, cycle charts, basic information and real-time news information, financial analysis, company introduction, dividends and dividend information, you can also use Moomoo to open an account to trade EFFECTOR THERAPEUTICS stocks，we will provide investors with reference decision data. Find real-time EFTR - eFFECTOR Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Effector Therapeutics started at buy with $20 stock price target at Mizuho MarketWatch. NasdaqCM - NasdaqCM Real Time Price. View a stock's price, volume, volatility and other statistics, as well as a price chart, news, performance vs. peers and a company profile. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. 08:01 AM ET Stocks USA. The stock price of eFFECTOR Therapeutics (NASDAQ: EFTR) - a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, in collaboration with investigators at Baylor College of Medicine - increased by 25% during intraday . View the latest EFTR stock quote and chart on MSN Money. eFFECTOR Therapeutics Inc Change company Symbol lookup EFTR 7.37 1.66 (29.07%) Post-Market 0.06 (0.81%) 1,780. 06/11/2021 02:34:58 1-888-992-3836 Free . eFFECTOR Therapeutics is followed by the analysts listed above. eFFECTOR Therapeutics Stock Gains On Encouraging Preclinical Zotatifin Data In . Find the latest eFFECTOR Therapeutics, Inc. (EFTR) stock quote, history, news and other vital information to help you with your stock trading and investing. On average, they expect eFFECTOR Therapeutics' share price to reach $28.60 in the next year. • Debuted as publicly-traded next-generation oncology company under symbol EFTR. You can buy and sell eFFECTOR Therapeutics (EFTR) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. 5 analysts have issued twelve-month target prices for eFFECTOR Therapeutics' shares. Key Data. Dive Into Our Pipeline. Quote. Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols EFTR and EFTRW. Description. Overview Detailed Quote Charting Historical Prices. Partnership handshake. What are selective translation regulator inhibitors? ET on Tuesday, September. Real time eFFECTOR Therapeutics, Inc. (EFTR) stock price quote, stock graph, news & analysis. eFFECTOR Therapeutics (EFTR) stock price, charts, trades & the US's most popular discussion forums. Technical Events. effector.com BioTech Founded: 2012 Funding to Date: $152.08MM. Latest EFFECTOR THERAPEUTICS (EFTR) stock news, . . Get eFFECTOR Therapeutics Equity Warrant Exp 26th Aug 2026 (EFTRW:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. The company was founded in 2012 and is headquartered in San Diego, California. Stock quote and company snapshot for EFFECTOR THERAPEUTICS INC (EFTR), including profile, stock chart, recent news and events, analyst opinions, and research reports. Get a real-time eFFECTOR Therapeutics, Inc. (EFTR) stock price quote with breaking news, financials, statistics, charts and more. Pfizer and eFFECTOR Therapeutics inked a global license and collaboration deal to develop small-molecule inhibitors of eukaryotic initiation factor 4E, also known as eIF4E. The Column Group and Alexandria Venture Investments are the most recent investors. EFTR stock quote, chart and news. With respect to the Incentive Plan Proposal, the votes were as follows: FOR AGAINST ABSTAIN NON-VOTES . The Investor Relations website contains information about eFFECTOR Therapeutics's business for stockholders, potential investors, and financial analysts. Proposal 3 - The "Incentive Plan Proposal" - to approve the eFFECTOR Therapeutics, Inc. 2021 Incentive Award Plan, including the initial share reserve under the plan. It focuses on small molecule drugs that act by selectively regulating translation that is known as protein synthesis. Class B Common Stock: FOR AGAINST ABSTAIN NON-VOTES 4,511,250 0 0 0 3. Source: Forbes World, Symbol: EFFECTOR THERAPEUTICS INC. - COMMON STOCK. Effector Therapeutics started at hold with $20 stock price target at Stifel Nicolaus MarketWatch. Buy or sell eFFECTOR Therapeutics stock. LWAC Stock: eFFECTOR Therapeutics SPAC Merger News Sends Shares Skyrocketing The merger will likely close today August 25, 2021 By William White , InvestorPlace Writer Aug 25, 2021, 12:44 pm EDT . eFFECTOR Therapeutics, Inc. (EFTR) stock plummeted over -2.81% intraday to trade at $-0.09 a share on NASDAQ. Historical daily price data is available for up to two years prior to today's date. Cancer is a complex . Real-Time News, Market Data and Stock Quote for EFFECTOR THERAPEUTICS eFFECTOR Therapeutics and Locust Walk Acquisition Corp. CSVI Crosses Above Key Moving Average Level. Latest stock price today and the US's most active stock market forums. EFTR - eFFECTOR Therapeutics Inc Stock quote - CNNMoney.com Markets eFFECTOR Therapeutics (EFTR) stock price, charts, trades & the US's most popular discussion forums. Company Overview More. Stock Effector Therapeutics Company Releases for eFFECTOR Therapeutics Inc. Wednesday, November 24, 2021. Webull offers eFFECTOR Therapeutics Inc (EFTRW) historical stock prices, in-depth market analysis, NASDAQ: EFTRW real-time stock quote data, in-depth charts, and a fully built financial calendar to help you invest smart. And we believe these are within reach. Our data shows that SR One Capital Management, LP is the largest shareholder with 17% of shares outstanding. eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Dive deeper with interactive charts and top stories of EFFECTOR THERAPEUTICS, INC. 06:49 AM ET. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. We note that hedge funds don't have a meaningful investment in eFFECTOR Therapeutics. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics . Get eFFECTOR Therapeutics Inc (EFTR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. eFFECTOR Therapeutics, Inc. (EFTR) Add to watchlist. This security was issued by eFFECTOR Therapeutics, Inc., whose common stock symbol is EFTR. 52wk Low 6.59. News. eFFECTOR Therapeutics, Inc. Common Stock (EFTR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. eFFECTOR Therapeutics stock quote and EFTR charts. eFFECTOR Therapeutics, Inc. Wall Street Stock Market & Finance report, prediction for the future: You'll find the eFFECTOR Therapeutics share forecasts, stock quote and buy / sell signals below. EFTR | Complete eFFECTOR Therapeutics Inc. stock news by MarketWatch. According to present data eFFECTOR Therapeutics Inc - Warrants (26/08/2026)'s EFTRW shares and potentially its market environment have been in bearish . Free forex prices, toplists, indices and lots more. While EFTR stock has escaped the usual underperformance of SPAC IPOs so far, eFFECTOR Therapeutics still remains a risky proposition. Effector Therapeutics has raised a total of $220M in funding over 6 rounds. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Operating Status Active. Short Term. Gross . During the post-SPAC spectacle, EFTR stock be volatile - this should be expected. eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. EFTR eFfector Therapeutics $6.04 / +0.3 (+5.23%) 11/08/21 Stifel eFfector Therapeutics upgraded to Buy at Stifel on NSCLC optimism 11/08/21 Stifel eFfector Therapeutics upgraded to Buy from Hold at Stifel 10/12/21 Credit Suisse eFfector Therapeutics initiated with an Outperform at Credit Suisse 10/04/21 Mizuho Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment . Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. But more importantly, we are a team that knows patients deserve more effective treatment options. Company profile page for eFFECTOR Therapeutics Operations Inc including stock price, company news, press releases, executives, board members, and contact information 01-21:56 GMT. Webull offers eFFECTOR Therapeutics Inc (EFTR) historical stock prices, in-depth market analysis, NASDAQ: EFTR real-time stock quote data, in-depth charts, and a fully built financial calendar to help you invest smart. The company was incorporated in 2012 and is based in San Diego, California. 6.99 +1.28 (+22.46%) As of 12:13PM EST. For more data, Barchart Premier members can download more historical data (going back to Jan. 1, 1980) and can download Intraday, Daily, Weekly, Monthly or Quarterly data on the Historical Download tab.Additional underlying chart data and study values can be downloaded using the Interactive Charts. Get eFFECTOR Therapeutics, Inc.'s stock price today. eFFECTOR Therapeutics (NASDAQ: EFTR) stock price, news, charts, stock research, profile. The company was incorporated in 2012 and is based in San Diego, California. Monday, September 20, 2021. SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended . A high-level overview of eFFECTOR Therapeutics Inc (EFTR) stock. eFFECTOR is made up of industry veterans who have played crucial roles in drug discovery and development. eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). This suggests a possible upside of 375.9% from the stock's current price. Their forecasts range from $20.00 to $50.00. eFFECTOR Therapeutics Stock. eFFECTOR Therapeutics, Inc., a biotechnology company, develops selective translation regulators for the treatment of cancer and other serious diseases. Stock Details. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Enter Company or Symbol. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with . Market open. Legal Name eFFECTOR Therapeutics, Inc. Stock Symbol NASDAQ:EFTR. eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Contact Email info@effector.com. View real-time stock prices and stock quotes for a full financial overview. eFFECTOR Therapeutics . Edit Profile. Dive deeper with interactive charts and top stories of EFFECTOR THERAPEUTICS, INC. A high-level overview of eFFECTOR Therapeutics Inc (EFTR) stock. Complete eFFECTOR Therapeutics Inc. Wt stock information by Barron's. View real-time EFTRW stock price and news, along with industry-best analysis. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies. This is why it happened. August 25, 2021 19:18 ET | Source: eFFECTOR Therapeutics, Inc. Free forex prices, toplists, indices and lots more. eFFECTOR Therapeutics is followed by the analysts listed above. Wall Street Stock Market & Finance report, prediction for the future: You'll find the eFFECTOR Therapeutics Inc - Warrants (26/08/2026) share forecasts, stock quote and buy / sell signals below. eFFECTOR Therapeutics Inc NASDAQ Updated Dec 6, 2021 9:35 PM. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor . Check out our EFTR stock analysis, current EFTR quote, charts, and historical prices for Effector Therapeutics Inc stock GlobeNewswire +5.84%. Currency in USD. Pfizer and eFFECTOR Ink $507 Million Cancer Deal. San Diego, CA - November 8, 2021 - eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. This factor is activity in a range of cancers and focuses on what is being dubbed the translatome—which is the area of cells where DNA is translated into proteins. eFFECTOR Therapeutics, Inc., a biotechnology company, develops selective translation regulators for the treatment of cancer and other serious diseases. The stock price of eFFECTOR Therapeutics (NASDAQ: EFTR) increased by 25% during intraday trading. eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Please note that any opinions, estimates or forecasts regarding eFFECTOR Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of eFFECTOR Therapeutics or its management. Effector Therapeutics is registered under the ticker NASDAQ:EFTR . Effector Therapeutics has a post-money . eFFECTOR's STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK). EFFECTOR THERAPEUTICS, INC. : Stock quote, stock chart, quotes, analysis, advice, financials and news for share EFFECTOR THERAPEUTICS, INC. | Nasdaq: EFTR | Nasdaq Pfizer and eFFECTOR Therapeutics inked a global license and collaboration deal to develop small-molecule inhibitors of eukaryotic initiation factor 4E, also known as eIF4E. Complete eFFECTOR Therapeutics Inc. stock information by Barron's. View real-time EFTR stock price and news, along with industry-best analysis. eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. It focuses on small molecule drugs that act by selectively regulating translation that is known as protein synthesis.

Rambling Man Laura Marling, Cheap Carbon Mountain Bike Frame, Things To Photograph Book, Rebels Showcase Schedule 2021, Tudn Spectrum Los Angeles,